Intra-Cellular Therapies (ITCI) : 5 analysts are covering Intra-Cellular Therapies (ITCI) and their average rating on the stock is 1, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.
Intra-Cellular Therapies (ITCI) : 7 investment research analysts covering Intra-Cellular Therapies (ITCI) have an average price target of $76.57 for the near short term. The highest target price given by the Brokerage Firm to the stock is $95 and the lowest target is $57 for the short term. Analysts expect the variance to be within $15.04 of the average price.
Shares of Intra-Cellular Therapies, Inc. rose by 2.23% in the last five trading days and 2.54% for the last 4 weeks. Intra-Cellular Therapies, Inc. is up 13.68% in the last 3-month period. Year-to-Date the stock performance stands at -21.99%. Intra-Cellular Therapies (NASDAQ:ITCI): stock turned positive on Tuesday. Though the stock opened at $41.19, the bulls momentum made the stock top out at $42.36 level for the day. The stock recorded a low of $40.8 and closed the trading day at $41.96, in the green by 2.37%. The total traded volume for the day was 458,082. The stock had closed at $40.99 in the previous days trading.
ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.